Viridian Therapeutics, Inc. Common Stock

HighVista Strategies sold 238,243 shares of Viridian Therapeutics (worth ~$7.08 million) in Q1 2026, reducing its position by $8.97 million when accounting for stock price movements. The sale may reflect profit-taking ahead of the company's June 30 FDA decision on its lead therapy veligrotug. Despite recent stock volatility following Phase 3 data...

Kopp Family Office reduced its Viridian Therapeutics stake by 117,878 shares ($3.5M) in Q1 2026, cutting the position from 3.4% to 0.7% of AUM. The move appears prescient as Viridian shares have fallen 50% since mid-March following disappointing Phase 3 data for elegrobart and stronger competing results from Amgen's Tepezza variant, raising quest...

Johnson Fistel, PLLC is investigating potential securities fraud claims on behalf of investors in J.Jill, RH, and Viridian Therapeutics. The J.Jill investigation was prompted by the company's March 31, 2026 earnings disclosure revealing poor holiday assortment performance, increased competitive promotions, and customer migration toward discounted...

Johnson Fistel, PLLP announced investigations into potential securities law violations by Viridian Therapeutics, Braskem S.A., and TAT Technologies Ltd. on behalf of investors who suffered losses. The investigation into Viridian focuses on whether the company complied with federal securities laws following its announcement of Phase 3 clinical tri...

Commodore Capital completely exited its 3.2 million share position in Viridian Therapeutics (worth $69 million) on February 17, 2026, reducing the holding from 3.4% of the fund's assets to zero. This comes despite Viridian's stock being up 75% over the past year and entering a catalyst-heavy 2026 with FDA approval decisions and Phase 3 data expec...